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Abstract
Background: Since July 1998 all Dutch women (± 200,000/y) are screened for red cell antibodies,
other than anti-RhesusD (RhD) in the first trimester of pregnancy, to facilitate timely treatment of
pregnancies at risk for hemolytic disease of the fetus and newborn (HDFN). Evidence for benefits,
consequences and costs of screening for non-RhD antibodies is still under discussion. The
screening program was evaluated in a nation-wide study. As a part of this evaluation study we
investigated, according to the sixth criterium of Wilson and Jüngner, the acceptance by pregnant
women of the screening program for non-RhD antibodies.
Methods: Controlled longitudinal survey, including a prenatal and a postnatal measurement by
structured questionnaires. Main outcome measures: information satisfaction, anxiety during the
screening process (a.o. STAI state inventory and specific questionnaire modules), overall attitude
on the screening program. Univariate analysis was followed by standard multivariate analysis to
identify significant predictors of the outcome measures. Participants: 233 pregnant women,
distributed over five groups, according to the screening result.
Results: Satisfaction about the provided information was moderate in all groups. All screen-
positive groups desired more supportive information. Anxiety increased in screen- positives during
the screening process, but decreased to basic levels postnatally. All groups showed a strongly
positive balance between perceived utility and burden of the screening program, independent on
test results or background characteristics.
Conclusion:  Women highly accept the non-RhD antibody screening program. However,
satisfaction about provided information is moderate. Oral and written information should be
provided by obstetric care workers themselves, especially to screen-positive women.
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Introduction
The scope of prenatal screening has considerably widened
last two decades. The number of tests increased, and the
time frame expanded to preconceptional. While consen-
sus exists about the restriction to evidence-based tests for
routine use, the benefits and burden of many tests in cur-
rent use are poorly documented, as is the case for screen-
ing for red blood cell (RBC) antibodies, other than
Rhesus-D (RhD).
Screening for non-RhD antibodies in all pregnant women
has been implemented in most developed countries. In
the Netherlands, screening for those so called non-RhD
antibodies, was introduced in 1998 in absence of evi-
dence of its effectiveness and costs [1,2].
Clinically relevant non-RhD antibodies can cross the pla-
centa and may, like RhD antibodies, induce hemolytic
disease of the fetus and newborn (HDFN). HDFN is a seri-
ous condition that can give rise to fetal hydrops, fetal
death or neonatal hyperbilirubinemia, resulting in perma-
nent neurological damage by kernicterus.
The obvious objective of the non-RhD screening program
is timely detection of pregnancies at risk of severe HDFN,
as this condition can be effectively treated by intra uterine
transfusions and/or postnatal exchange transfusions in
severe cases, or by postnatal phototherapy and/or blood
transfusions in moderate cases [3-5]. Moreover, screening
during pregnancy facilitates quick identification of the
specificity of detected antibodies, if a blood transfusion to
the mother is necessary during delivery.
Despite the face validity of this approach, which facili-
tated its introduction, empirical evidence is limited com-
pared to the evidence supporting screening for RhD
antibodies. For this reason the Dutch screening program
was evaluated in a nation-wide study [6]. The results of
this study show that, if we compare screening for non-
RhD antibodies and for RhD antibodies, the prevalence of
non-RhD antibodies is about fourfold (328/100,000 ver-
sus 75/100,000). However, the number needed to screen
(NNS) do detect severe HDFN, due to non-RhD antibod-
ies is 20,000, compared to 4,000 to detect severe HDFN by
RhD antibodies This is due to two reasons. First, many
pregnant women show non-RhD antibodies due to previ-
ous blood transfusions (transfusions are RhD matched).
For this reason in about 40% of the non-RhD positive
pregnancies the father – and also the fetus – is antigen-
negative for the blood group antigen against which the
maternal antibodies are directed; in these cases the fetus is
not at risk of developing HDFN [6]. In case of RhD anti-
bodies almost all fathers are antigen-positive, which
underlies the observed immunization [7]. Second, among
many non-RhD antibodies, only few (only anti-K, anti-c,
anti-C, anti-e and anti-E) actually can cause severe HDFN
[3,6]. Combining probabilities it turns out that about
1:50 of pregnancies with non-RhD antibodies results in
severe HDFN versus 1:4 of pregnancies with RhD-anti-
bodies [6].
Because of the high NNSs of the non-RhD screening pro-
gram compared to RhD screening, the acceptance of the
non-RhD screening program by pregnant women, a pre-
requisite following the Wilson & Jüngner criteria [8], is in
particular important.
This paper explores the attitude towards the screening
program among several groups of pregnant women, relat-
ing acceptance to being informed and experienced bur-
den. Also it reports the experienced burden of the
screening process in all its stages. This report is part of a
nation-wide evaluation study on non RhD screening to
address expressed public and professional concern on this
prenatal program.
Methods
National screening program
RBC antibody screening is part of the booking visit proto-
col, and free of charge. The obstetric care worker (inde-
pendent midwife 75%, general practitioner 5%,
obstetrician 20%, [9] is responsible. The screening test is
performed by local laboratories (n = ± 90), resulting in
1.2% positive screening results. Blood of screen-positives
is sent to one of two specialized national reference labora-
tories. After confirmation of the positive screen result
(20% is not confirmed), the reference laboratory deter-
mines the antibody specificity. In 47% of screen-positive
pregnancies clinically non-relevant antibodies are found
(not able to cross the placenta, so not causing HDFN), in
33% clinically relevant (HDFN causing) antibodies are
detected. [6] In those pregnancies the paternal antigen
pattern is typed, because only if the father is antigen-pos-
itive, the fetus is at risk of HDFN. Pregnancies at risk are
monitored by repeated laboratory testing in the reference
laboratories. If testing suggests a major risk of HDFN,
women are clinically monitored, by ultrasound, Doppler
flow measurement and, rarely, by amniocentesis (fetal
antigen genotyping and/or Liley Index). The most severe
cases of HDFN are monitored and – if necessary – treated
with intra uterine transfusions in one expert centre [10].
Study design
A controlled longitudinal survey was performed, includ-
ing a prenatal measurement around week 20 and a post-
natal measurement two weeks after birth, using structured
questionnaires.
To create a longitudinal perspective on both occasions
questions referred to actual experiences and experiences in
the preceeding relevant period.BMC Pregnancy and Childbirth 2008, 8:49 http://www.biomedcentral.com/1471-2393/8/49
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The set of questions was based on a prespecified behavio-
ral model (Figure 1).
The study proposal was judged by the Ethical Committee
of the Academic Medical Centre in Amsterdam. This Com-
mittee established that this study design did not require
formal approval of the Committee.
All participants gave informed consent; at least moderate
command of the Dutch language was required.
Participants
Women from the following groups, ranked according to
the result of the screening and the confirmation test, were
included:
- Group A) controls (screen-negative);
- Group B) women with a positive screening result, how-
ever not confirmed by the reference laboratory; only
women, aware of their screen-positivity, were included;
during the study it appeared that many care workers did
not reveal the initial screen-positive test to the woman;
- Group C) women with clinically non-relevant RBC anti-
bodies (i.e. antibodies that cannot cause HDFN);
- Group D) women with clinically relevant non RhD anti-
bodies, nevertheless not at risk of HDN because the father
was antigen-negative;
- Group E) women with clinically relevant non-RhD anti-
bodies, at risk of HDFN (father antigen-positive).
Women in group D and E also participated in the nation-
wide evaluation study of the non-RhD screening program.
We used a quota sampling method and intended at onset
to select at least 50 controls under midwifery care in the
first trimester of pregnancy and 50 controls under care of
Behavioral/attitudinal model screening for non RhD RBC antibodies Figure 1
Behavioral/attitudinal model screening for non RhD RBC antibodies.
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an obstetrician (hereafter referred to as 'hospital care'/
'hospital practices'), as well as 50 women from each of the
screen-positive groups (B, C, D, E). We expected that 50%
of the selected women would complete both question-
naires.
Pregnant women were enrolled by the obstetric care
worker during the second prenatal visit or, if screen-posi-
tive, as soon as the results of the confirmation test in the
reference laboratories, as well as the paternal antigen typ-
ing, were known. Excluded were women with a miscar-
riage before the moment of inclusion.
Controls were selected in 23 randomly selected midwifery
practices (response 23/28 = 82%) and 17 hospital prac-
tices (response 17/22 = 77%) in May-June 2005.
Midwives were asked to select four and obstetricians to
select two or – if possible – three random controls on the
base of having a similar date of communication of the
screening test result to the pregnant woman (or coming
closest to that date). Screen-positive women (groups B, C,
D, E) were consecutively identified at the two reference
laboratories from April-June 2005 and included via the
obstetric care worker. The numbers of eligible women
who were actually asked by the obstetric care worker to
participate in the study by the obstetric care worker, were
not registered in the groups of women without clinically
relevant antibodies (A, B and C).
Command of the Dutch language was at the judgement of
the obstetric care worker.
Behavorial/attitudinal model
A conceptual model was developed ex ante to elucidate
the relation between the process of antibody screening,
personal maternal characteristics, setting of care and
maternal circumstances, satisfaction about the provided
information, anxiety during the screening process, and the
overall attitude towards the screening. (Figure 1). The
model was based on similar models that are used in the
evaluation of (pregnancy) screening [11-14].
Two validated questionnaires were used:
- Multidimensional Health Locus of Control (MHLC),
consisting of 18 items, distributed over three subscales
with each six items: 'internal', 'chance' and 'powerful oth-
ers'. MHLC sum scores were calculated per subscale. If
more than two items were missing within one subscale,
the subscale score was missing. One or two missing items
were substituted by the mean of the non-missing items in
the subscale [15].
- Spielberger's State-Trait Anxiety Inventory Questionnaire
(STAI), to measure general background anxiety (STAI
trait) and general situational anxiety (STAI state). Each
questionnaire consists of 20 items with four response cat-
egories with a range of 20–80. The STAI-scores were only
calculated if at least 17 items (out of 20) were filled out.
For three or less missing items a value of 2.0 was substi-
tuted [16,17].
Specific questionnaires were developed for this project,
based on existing formats:
- Knowledge on RBC antibodies and HDFN was derived
from the response to 17 yes/no questions.
- Screen-related anxiety at different stages of the screening
process was captured by eliciting self report data on the
level of anxiety before the test result (screening, reference
laboratory confirmation test, paternal antigen typing, lab-
oratory monitoring) was known, and on the level of relief,
reassurance and fright after hearing the test result. Women
had to tick a cross on a visual analogue scale (VAS) of 160
mm with four anchors (not at all (0 mm) – a little bit (55
mm) – rather (110 mm) – very much (160 mm)).
- Satisfaction about the availability and comprehensibility
of information, and the overall judgment of the screening
process were measured using a similar four anchor VAS
(very unsatisfied (0 mm) – unsatisfied (55 mm) – satis-
fied (110 mm) – very satisfied (160 mm)).
VAS are widely used in health care research, for example
for scaling of ranked differences between health states,
and for scaling of anxiety [18,19].
(all materials available from the first author).
Data collection
The prenatal questionnaire covered the MHLC, STAI trait
and STAI state, knowledge on RBC antibodies, screen-
related anxiety and satisfaction about provided informa-
tion until this moment. This questionnaire additionally
recorded personal characteristics and data on the obstetric
history. The postnatal questionnaire measured the course
of pregnancy and delivery, the STAI state, screen-related
anxiety, satisfaction about information, and the overall
judgement about the screening program.
All questionnaires were tested in a pilot study among
cases with clinically relevant antibodies and controls
(data not used in this study).
The prenatal questionnaire was offered by the obstetric
care worker around week 20, about 8 weeks after screen-
ing, and completed within a week, the postnatal question-BMC Pregnancy and Childbirth 2008, 8:49 http://www.biomedcentral.com/1471-2393/8/49
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naire was sent by post to the mother twelve days after the
actual date of birth or – if the date of birth was unknown
– after the expected date of birth. The women were
instructed to complete the questionnaire 14 days after the
actual day of birth. If this was not possible, the woman
was instructed to recall to mind her situation 14 days after
birth.
Data analysis
Prior to analysis the data of the controls under hospital
care were linearly weighted (factor 0.41)) to accommo-
date the actual 80%-20% balance of primary care worker
and secondary care worker involvement in early preg-
nancy. So doing, we excluded selection bias effects, as in
the Dutch obstetric organisation obstetric risk factors are
more prevalent in women under hospital care, and obstet-
ric risk factors as well as the setting of care may be related
to other background characteristics (for example anxiety),
influencing our main outcome measures.
Our behavorial/attitudinal model focuses on (1) informa-
tion satisfaction, (2) anxiety, and (3) overall attitude
towards the screening program, comparing the responses
of the predefined groups. For all three outcomes the rele-
vant cross table or figure is followed by standard explora-
tory multivariate analysis. Variables with a p-value <0.10
in the univariate analysis were offered forward to the mul-
tivariate model according to the time sequence of the
occurrence of these risk factors; models were checked for
interaction.
The VAS scores were measured in millimetres (from 0–
160) and divided through 16 to achieve a score from 0
until 10. A score of 0 reflects 'not at all', 3.4 ' a little bit',
6.9 'rather' and 10 'very much'.
Specific screen-related stress was distinguished in anxiety
before a test result was known and in the impact of the
result of a specific test. Anxiety was calculated as the mean
VAS score on 'anxiety about the test result' and 'thinking
about the test result'. The impact of the test result was cal-
culated from three items concerning the feelings of the
mother after hearing the test result: relief, reassurance and
fright according to the following formula: fright – MEAN
(relief, reassurance).
Satisfaction about information provided by the obstetric
care worker, was summarized in one sum score, calculated
as the mean of:
- the mean score on all questions regarding the amount of
information provided by the obstetric care worker, on dif-
ferent moments during the screening process
- the mean score on all questions regarding the compre-
hensibility of information, provided by the obstetric care
worker, (verbal and written) on different moments during
the screening process
- if there is a match between the mode of reporting the
screening result: 7; if there is no match: 3.
In the relevant cross tables outcomes, scored on a VAS, are
presented in three categories (VAS score < 3.4, VAS score
≥3.4 < 6.9, VAS score > 6.9), and analysed as categorical
variable as well as continuous variable. In the multivariate
analysis the continuous VAS scores are used.
All data were analysed with SPSS 11.0. Differences
between categorical variables were tested by Pearson's chi
square test or Fisher's exact test. Differences between
means of continuous variables were tested by ANOVA and
by the Student's t-test. A difference was considered as sig-
nificant if the p-value was < 0.05. The value in each group
was tested against the controls.
Results
Response
The response in women with clinically relevant antibodies
(D and E) was 90%. In the groups without clinically rele-
vant antibodies (A, B and C) the response rate was
unknown. In each group at least 50 women were selected.
The prenatal questionnaire was completed by 263; 233
(89%) also completed the second questionnaire (Table
1). In group B (positive screening, unconfirmed) less than
25 women completed both questionnaires. The reasons
for not completing the second questionnaire were
unknown.
Baseline characteristics
Table 2 outlines the baseline characteristics of the
respondents, according to the risk of HDFN, as estab-
lished upon the first trimester antibody screening. Cases
at risk (group E) differed from the other groups related to
known risk factors for antibody development [4]: a.o.
cases were more often multiparous, were older and were
more often under hospital care in early pregnancy. Cases
at risk (group E) reported more often women with RBC
antibodies in their environment, and had more knowl-
edge about RBC antibodies.
Availability of information; satisfaction with information
Table 3 outlines the availability and use of information.
Only half of the women in the groups A, B, C and E had
actually read the written information about RBC antibody
screening, which generally is provided by care workers. In
group D significantly more women (77%) reported to
have read the written information. The role of oral profes-
sional information increased with risk status: all womenBMC Pregnancy and Childbirth 2008, 8:49 http://www.biomedcentral.com/1471-2393/8/49
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with at risk of HDFN (group E) were informed orally. The
use of internet information showed the same pattern.
The majority of women, regardless the group with clini-
cally non-relevant RBC antibodies (group C), had a fairly
accurate account of the interpretation of results of the sub-
sequent antibody blood tests (detailed data available on
request). Only three of 93 controls erroneously thought
that RBC antibodies were present in their case. One
woman out of 21 with a non-confirmed positive screening
(group B) and nine women of 44 (20%) with clinically
non-relevant antibodies (group C) thought that they had
antibodies that for certain could harm the child.
Table 4 presents selected data on the satisfaction with the
information provided by the obstetric care worker. Per-
sonal communication, either at the office or by telephone,
was the strongly preferred mode of communication of the
screen result, regardless the risk status. In retrospect the
probability of a mismatch between preferred and actual
mode of communication increased according to risk sta-
tus from 16% in group A) to 38% in group E). Group E)
differed from the other screen-positive groups (B, C, D) in
the choice between information at the office versus by tel-
ephone, where no difference should be expected: this sur-
vey question refers to a stage where women do not know
to which group they will belong. The difference can be
explained by post hoc adjustment: once you know you are
at risk you might prefer in retrospect to have heard this by
telephone rather than at the next consult.
On average the satisfaction about the amount of and the
comprehensibility of provided information was moderate
in all groups. All screen-positive groups (B, C, D, E)
desired more supportive (preferably written) information,
prenatally (data not shown; not different from postnatal
data) and postnatally. Not one singular topic in need of
information prevailed.
In the multivariate analysis (Table 5) the summary score
on satisfaction about information was significantly corre-
lated with the STAI trait (the more anxious, the more dis-
satisfied), referral from primary to secondary care during
pregnancy (after referral more satisfied), and being screen-
positive (screen-positives more dissatisfied). The desire
for more information (not part of the summary score) was
also correlated with screen-positivity (screen-positives
wanted more info) and the STAI state in week 20 (the
more anxious, the more desire for information).
Anxiety
General background anxiety, as measured by the STAI
trait, was not related to the result of the screening test. The
STAI state in week 20 was lower in the group (B) with an
unconfirmed positive screening (28.9), compared to the
other groups (scores from 33.2 until 35.6)); after birth no
difference was found between the groups (Figure 2).
Specific anxiety (4 anchor VAS) apparently was related to
the screening process (Figure 3). Scores increased after the
positive screening result, waiting for the second blood
test, to a level between 'a little bit anxious' and 'rather anx-
ious'. From then onwards screen-related anxiety attenu-
ated to baseline (< 'a little bit anxious') in all groups.
Laboratory and clinical monitoring apparently reduced
rather than induced anxiety.
Our summary score on test result impact showed a 'bad'
impact (sumscore < 0, implying that the test results causes
more fright than reassurance and relief) of a positive test
result, and a 'good' impact (sumscore > 0) if no risk of
HDFN turned out to be present (Figure 4).
In the multivariate analysis (Table 5) anxiety about
mother and child two weeks after birth was significantly
correlated with the condition of mother and child at that
moment (more anxiety if mother and/or child were not
well), invasive procedures during delivery (cause more
anxiety), STAI trait (a higher score predicted more anxi-
ety), and the presence of HDFN in the environment (pre-
dicted more anxiety). The postnatal STAI state was
Table 1: Response according to HDFN risk, as established upon first trimester RBC antibody screening
Groups according to risk for HDFN Questionnaire 1 completed
no
Questionnaire 1 + 2 completed
no (%)
A1. controls midwifery practice, screening negative 61 58 (95)
A2. controls hospital practice, screening negative 41 35 (85)
B. positive screening result, not confirmed 24 21 (88)
C. clinically non-relevant antibodies 48 44 (92)
D. clinically relevant non-RhD antibodies, not at risk HDFN 
(father antigen-negative)
37 30 (81)
E. clinically relevant non-RhD antibodies, at risk HDFN 
(father antigen-positive)
52 45 (87)
Total 263 233 (89)
No significant differences in response between the groupsBMC Pregnancy and Childbirth 2008, 8:49 http://www.biomedcentral.com/1471-2393/8/49
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Table 2: Baseline characteristics, respondents grouped according to HDFN risk, as established upon first trimester RBC antibody 
screening
Controls Screen-positive, not at risk HDFN At risk HDFN
n = 733 Screen-pos, not-
confirmed
n = 21
Clinically non-relevant 
antibodies
n = 44
Non-RhD antibodies, 
father neg.
n = 30
Non-RhD antibodies, 
father pos.
n = 45
General
Age – yr mean (SD) 30.6 (4.2) 31.3 (3.7) 30.5 (4.8) 30.6 (4.2) 32.9 (3.4)*
Educational level – %
. elementary or lower secondary 
school
14 9 23 40* 9
. higher secondary school 37 43 36 30 49
. higher vocational level/university 49 48 41 30* 42
Ethnic group: non-Dutch – % 4 0 14 0 0
MHLC1 (range 6–36) – mean (SD)
Domains:
- Internal 22.1 (4.1) 22.5 (3.4) 21.7 (3.7) 21.5 (5.2) 21.7 (3.6)
- Chance 17.6 (3.6) 17.2 (4.8) 16.7 (3.9) 17.9 (5.6) 18.2 (4.5)
- Powerful others(doctors) 13.9 (3.6) 13.8 (3.4) 14.7 (4.0) 13.8 (4.0) 15.2 (4.1)
STAI trait – mean (SD) 34.0 (7.3) 31.4(6.3) 34.8 (8.3) 34.1 (7.8) 33.7 (7.9)
Disease specific experience
Known with RBC antibodies/HDFN 
– %
NA NA 23 30 27
RBC antibodies in environment – % 26 29 30 17 44*
HDFN in environment – % 10 10 0* 7 16
Knowledge about RBC antibodies 
(range:0–17) – mean (SD)
7.6 (4.1) 8.4 (3.5) 8.4 (4.0) 9.2 (4.1) 11.7 (3.4)*
Obstetric experience
History of former pregnancy/
delivery – %
51 62 66 63 96*
. former pregnancy/delivery with 
problems – %
19 10 23 10 33
Care during current pregnancy – %
- start in primary care 80 86 77 63 42*
- primary → sec care 
(% of) started in primary care)
35 39 29 32 42
Hospital admission in current 
pregnancy – %
14 10 25 23 22
Non-medical life-events in current 
pregnancy – %
43 33 43 37 27
Invasive procedure current 
delivery2 – %
33 29 21 30 27
Bad experience current delivery – 
%
18 33 21 23 11
Not well (mother and/or child) 14 
days after current delivery – %
12 14 7 21 4
1 Multidimensional Health Locus of Control Scales
2Invasive procedure delivery: assisted vaginal delivery, cesarean section, manual removal of placenta, surgical suturing
3Weighted controls from obstetric care: 35*0.41 = 15; 58 controls from midwifery care
* p < 0.05, compared to controlsBMC Pregnancy and Childbirth 2008, 8:49 http://www.biomedcentral.com/1471-2393/8/49
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correlated with essentially the same variables: STAI trait
and the current condition of mother and child.
Overall attitude
The majority of women considered the burden of the non-
RhD antibody screening as low, prenatally as well as post-
natally, however with significant higher scores in screen-
positive women (Table 6). Most women in all groups con-
sidered the non-RhD antibody screening as useful; only
women with clinically non-relevant antibodies more fre-
quently considered the screening as not useful. See Table
6.
All groups considered the perceived balance between use-
fulness and burden of the current screening program
strongly in favour of antibody screening. In women at risk
of HDFN (group E) the mean VAS score (not reported in
Table 6) on this balance for themselves was higher than in
the control group (p = 0.036), while the proportion of
women with a score 'important' was slightly higher (no
significance).
The multivariate analysis (Table 5) did not identify varia-
bles – in particular no risk or test relevant variables –
explaining the overall attitude (from the perspective of
other women) towards red cell antibody screening.
Discussion
Our study shows that some psychological impact of preg-
nancy screening for non-RhD RBC antibodies exists in
terms of anxiety, which is temporary and never unaccept-
able. Screen-positive women clearly experience a need for
more information than provided, where universal prefer-
ence for personal communication (rather than letters or e-
mail) is stated. The overall attitude towards RBC antibody
screening in pregnancy is strongly positive and does not
depend on the screening result. Although screen-positive
women experience some anxiety especially during the
period of uncertainty about the actual HDFN risk status,
they judge the balance between utility and burden of the
screening process to be strongly positive. The anxiety level
two weeks after birth does, reassuringly, not depend on
the screening result or risk factors in this regard, but only
on pre-existing background personal and clinical charac-
teristics of the women.
Most literature about the attitude towards screening dur-
ing pregnancy and the role of information concerns
screening for maternal HIV status or for congenital mal-
formations, conditions with a quite different impact on
mother and child compared to the presence of non-RhD
antibodies. Our results can best be compared with two
prospective studies on screening for gestational diabetes
[12,20]. Kerbel et al. show that positive-screened women
feel more unsure shortly after screening; later in preg-
nancy there is no difference with negative-screened wom-
enBoth studies on gestational diabetes screening show no
differences in anxiety (STAI trait) and depression between
women with a positive and a negative screen result.
Unlike our results screen-positive and screen-negative
Table 3: Received information about antibodies and HDFN, according to HDFN risk, as established upon first trimester RBC antibody 
screening
Controls Screen-positive, not at risk HDFN At risk HDFN
n = 731 Screen-pos, not-
confirmed
n = 21
Clinically non-relevant 
antibodies
n = 44
Non-RhD antibodies, 
father neg.
n = 30
Non-RhD-antibodies, 
father positive
n = 45
Mode of reporting result screening for RBC antibodies
- regular consult – % 84 67 73 64* 36*
- telephone 4 29* 16* 23* 44*
- letter 3 4 9 10 9
- other way 1 0 2 3 7
- not reported 8 0 0 0 4
Information read in written information, provided by obstetric care worker?
Yes – % 51 43 55 77* 49
Verbal information provided by obstetric care worker
Yes – % 65 76 84* 90* 96*
Information sources found by the woman herself
(more than one source possible)
- written – % 45 19* 21* 33 16*
- internet 10 19 27* 30≈ 53*
- friends/family 21 14 11 23 27
- education 18 24 5* 7 7
- OPZI-study 2 0 0 0 23* 13*
- other sources 4 5 0 0 7
1 Weighted controls from hospital care: 35*0.41 = 15; 58 controls from midwifery care
2 OPZI-study: nation-wide evaluation of the first screening program for RBC antibodies, other than RhD
* p < 0.05, differences compared to controlsBMC Pregnancy and Childbirth 2008, 8:49 http://www.biomedcentral.com/1471-2393/8/49
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women were satisfied about the explanation given about
the screening test and the screening result. The difference
may be explained by the complexity of non-RhD immuni-
zation with concomitant complex screening procedure
compared to gestational diabetes, which is more easily
explained. An alternative explanation is that well
informed women are more aware of the complexity and
the remaining gaps in the received information. Put to the
extreme: the wish for more information indicates that
information provision has been successful, rather than
unsuccessful.
No previous studies offer explicit judgement on RhD or
non-RhD RBC antibody screening, preventing compari-
son of our overall judgment results with others.
Our measurement design included asking women on
experiences/attitudes in the recent past. This can cause
some bias in the measurement of anxiety around the first
and second blood test and during laboratory and clinical
monitoring. Some research induced anxiety cannot be
avoided, if so many questions are asked about anxiety
during the different stages of the screening process. How-
ever, anxiety is measured in all groups according to the
Table 4: Satisfaction about information on RBC antibodies and HDFN, according to HDFN risk, as established upon first trimester 
RBC antibody screening
Controls Screen-positive, not at risk HDFN At risk HDFN
n = 731 Screen-pos, not-
confirmed
n = 21
Clinically non-
relevant antibodies
n = 44
Non-RhD 
antibodies, father 
neg.
n = 30
Non-RhD 
antibodies, father 
pos.
n = 45
Info from obstetric care worker
- amount of info
. dissatisfied2 -% 3 5 5 13 4
. not really satisfied 82 76 86 64 71
. satisfied 15 19 9 23 25
- comprehensibility info
. dissatisfied -% 1 5 5 3 2
. not really satisfied 82 62 90 74 67
. satisfied 17 33 5 23 31
Preferred mode of communication result of RBC antibody screening
- regular consult -% 93 57* 77* 90 60*
- telephone 3 24* 9 10 40*
- letter 3 14 7 0 0
- other way 1 5 7 0 0
Mismatch of preference versus 
actual mode of communication -
%
16 19 30 30 38*
Sumscore satisfaction on information from obstetric care worker[
. dissatisfied2 -% 3 5 7 10 4
. not really satisfied 65 76 70 73 80
. satisfied 32 19 23 17 16
Wish for more info 2 weeks after 
birth -%
21 67* 54* 43* 69*
. written 18 62* 47* 37* 53*
. verbal 8 19 21* 20 27»
. internet 3 33* 9 10 20*
. other way 1 10 5 10 11*
-Topics about which more information is wished (More than one topic possible)
. consequences child -% 15 57* 46* 33* 60*
. consequences mother 14 57* 41* 33* 47*
. treatment child 8 24 18 13 47*
. next pregnancy 7 33* 25* 20 42*
. blood testing 10 38* 16 13 24*
. other topics 0 5 0 0 11*
1 Weighted controls from hospital care: 35*0.41 = 15; 58 controls from midwifery care
2 Dissatisfied: VAS score < 3.4; not really satisfied: VAS score between 3.4 and 6.9; satisfied: VAS score >= 6.9 (see methods)
* p < 0.05, differences compared to controlsBMC Pregnancy and Childbirth 2008, 8:49 http://www.biomedcentral.com/1471-2393/8/49
Page 10 of 14
(page number not for citation purposes)
Table 5: Significant predictors (p < 0.05) of main outcome measures on RBC antibody screening in multivariate analysis
Satisfaction on information Anxiety 2 weeks after birth Balance usefulness-burden 2 weeks after 
birth
sumscore info 
satisfaction
wish more info 2 
weeks after birth
pregnancy-related 
anxiety
general anxiety: 
STAI state
for myself for others
Standardized β Exponent B Standardized β Standardized β
STAI trait - 0.20 0.16 0.41
STAI state 20 
weeks
1.04
HDFN in 
environment
0.14
Screen-positivity -.0.17 5.1
At risk HDFN 
(group E)
0.143
Referral during 
pregnancy
0.17
Invasive procedure 
delivery
0.18
Mother and/or 
child not well 2 
weeks after birth
0.40 0.31
R square 0.09 0.16 0.29 0.28 0.02
General anxiety, according to HDFN risk status Figure 2
General anxiety, according to HDFN risk status.
*
* p<0.05, compared to controls (A)
A
B
C
D
E
20
22
24
26
28
30
32
34
36
38
40
STAI trait STAI state 20 weeks
pregnant
STAI state 2 weeks after
birth
20
22
24
26
28
30
32
34
36
38
40
STAI trait STAI state 20 weeks
pregnant
STAI state 2 weeks after
birth
controls (A) non-confirmed positive screen (B)
clinically non-relevant antibodies (C) clinically relevant antibodies, not at risk (D)
clinically relevant antibodies, at risk (E)BMC Pregnancy and Childbirth 2008, 8:49 http://www.biomedcentral.com/1471-2393/8/49
Page 11 of 14
(page number not for citation purposes)
same procedure. Therefore, the differences and the impact
of the various screening results can we interpreted in a
meaningful way.
We did not include non-Dutch speaking women (± 5% of
the population), so conclusions about this group cannot
be drawn. Because there was no information about the
proportion of eligible women without clinically relevant
antibodies who actually participated in the study, we can-
not be sure that our study population was representative
for the whole population of Dutch-speaking pregnant
women. However, in our multivariate analysis back-
ground characteristics did not emerge as significant pre-
dictors for information satisfaction, anxiety or overall
attitude. Theoretically it is possible that this is due to
selective non-response of women with specific back-
ground characteristics. However, it is unlikely that selec-
tive non-response will substantially change our
conclusions.
In the Dutch setting of obstetric care provision of ade-
quate explicit information on all standard screening tests
during pregnancy is required (political imperative). In
other countries standard screening tests may be per-
formed without saying, avoiding some 'information
induced' anxiety and curiosity.
Conclusion
From our study it can be concluded that the adverse psy-
chological effects of non RhD antibody screening, espe-
cially in women with a false positive test (not-confirmed
positive screening or clinically non-relevant antibodies),
are less important compared with the benefits in the small
group of pregnancies with HDFN. Assuming that the non-
RhD antibody screening program fulfils the other criteria
of Jüngner and Wilson, our study primarily provides some
issues for improvement:
- Written information should be distributed by obstetric
care workers themselves, especially to screen-positive
women;
- This information should describe the implications for
mother and child of clinically relevant antibodies, but
Specific screening related anxiety during screening process until 2 weeks after birth, according to HDFN risk status Figure 3
Specific screening related anxiety during screening process until 2 weeks after birth, according to HDFN risk 
status.
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also of clinically non-relevant antibodies. Information
about this last topic is very limited in the available book-
lets. It should be clear that in presence of clinically non-
relevant antibodies there is no risk at all for mother and
child;
- All important results, including a positive screen result,
should be communicated personally to the pregnant
woman;
- Theoretically one could consider pre test measurement
of background anxiety (i.e. STAI) to select women who are
more likely to develop high levels of anxiety if offered pre-
natal tests or during the test procedures. In view of increas-
ing intensity of prenatal and even preconceptional
screening programs, this consideration in our view is no
longer theoretical given the strong effect of background
anxiety and the possible predictive value for the course of
pregnancy and delivery [21]. However, such an approach
would also require obstetric care workers to be better
equipped.
In conclusion we can say that the non-RhD antibody
screening program is fully acceptable to pregnant women
and fulfils the sixth criterium of Wilson and Jüngner,
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Impact of results of blood testing to determine HDFN risk status, according to risk status Figure 4
Impact of results of blood testing to determine HDFN risk status, according to risk status.
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Table 6: Opinion about burden and usefulness of RBC antibodies and HDFN 2 weeks after birth, according to HDFN risk, as 
established upon first trimester RBC antibody screening
Controls Screen-positive, not at risk HDFN At risk HDFN
n = 731 Screen-pos, not-
confirmed
n = 21
Clinically non-relevant 
antibodies
n = 44
Non-RhD antibodies, 
father neg.
n = 30
Non-RhD-antibodies, 
father positive
n = 45
%% % % %
Perceived burden of the screening process 20th week of pregnancy
.no burden 2 99 52* 45* 60* 29*
.some burden 1 48 55 30 62
.significant burden 0 0 0 10 9
Perceived burden of the screening process 2 weeks after birth
.no burden 2 99 67* 51* 67* 47*
.some burden 1 33 49 27 47
.significant burden 0 0 0 6 6
Opinion on usefulness of the screening 2 weeks after birth
.not useful 2 81 9 2 2 * * 1 3 4
.some usefulness 60 43 45 57 56
.significant usefulness 32 38 33 30 40
Opinion on balance usefulness versus burden of screening 2 weeks after birth
for myself
. unimportant 2 70 9 4 4
. some importance 42 62 47 46 29
. important 51 38 44 50 67
for others
. unimportant 5 5 12 4 4
. some importance 46 52 38 46 35
. important 49 43 50 50 61
1 Weighted controls from hospital care: 35*0.41 = 15; 58 controls from midwifery care
2 No burden/not useful/unimportant: VAS score < 3.4; some burden/usefulness/importance: VAS score between 3.4 and 6.9; significant burden/
usefulness/important: VAS score >= 6.9 (see methods).
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